Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Immune Checkpoint Inhibitors – Access & Reimbursement – Access and Reimbursement – Immune Checkpoint Inhibitors: Top Five European Markets (EU)
Immune checkpoint inhibitors, including Bristol-Myers Squibb’s Opdivo, Merck & Co.’s Keytruda, and Roche’s Tecentriq, are revolutionizing the therapeutic strategies for several cancers. This…
Amyotrophic Lateral Sclerosis | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2019
Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disorder that leads to progressive muscle wasting and weakness. The typical survival time is three to five years from onset. The…
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Detailed, Expanded Analysis: Special Focus on Retinal Therapies: US Payer Management of the Medical Benefit
As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to impose…
Special Focus on Retinal Therapies: Payer Management of the Medical Benefit | Access & Reimbursement | US | 2019
As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to impose…
